StockNews.AI
MRNA
CNBC
50 days

Moderna's flu vaccine shows positive late-stage trial results, paving way for combination Covid shot

1. Moderna's flu vaccine showed stronger immune response in late-stage trial. 2. Plans to resubmit applications for standalone and combination flu-Covid vaccines. 3. Efficacy results show 26.6% improvement over standard flu vaccines. 4. Seasonal flu hospitalizations reached a 15-year high, underscoring vaccine need. 5. Moderna's stock is down 30% this year amid regulatory uncertainties.

5m saved
Insight
Article

FAQ

Why Bullish?

Positive trial data and planned regulatory submissions may restore investor confidence, akin to previous vaccine approvals that boosted MRNA shares substantially.

How important is it?

The recent trial results and upcoming regulatory strategies are crucial for MRNA's future market positioning, particularly given the competition.

Why Long Term?

Successful approvals could lead to significant revenue streams from flu and combination vaccines over the coming years, similar to the success seen with its COVID-19 vaccine.

Related Companies

Related News